Skip to main content

Table 2 Percentage of treatment-related adverse events

From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Adverse event

Percentage

Fatigue

6.4

Diarrhea

5.1

Constipation

4.5

Insomnia

4.5

Vomiting

2.9

Anemia

2.6

Headache

2.6

Dizziness

2.3

Dyspnea

2.3

Rash

2.3

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us